A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 52-Week Study to Assess the Efficacy and Safety of Etrasimod in Subjects With Moderately to Severely Active Ulcerative Colitis

Project: Research project

Project Details

StatusFinished
Effective start/end date5/11/20 → 5/11/23

Funding

  • DrugDev Inc. (APD334-301 // APD334-301)
  • Arena Pharmaceuticals, Inc. (APD334-301 // APD334-301)